DEF 14A: Pineapple Financial Seeks Shareholder Approval for $100M Capital Raise

Pineapple Financial Inc. is holding a special meeting to approve the issuance of 24.6 million common shares for a $100 million private placement and to remove share transfer restrictions.

Summary

• A Special Meeting of Shareholders will be held on October 31, 2025, at 9:30 a.m. Eastern Time, to vote on two key proposals.
• Proposal 1 seeks approval for the issuance of 24,642,700 common shares (SR Common Shares) in exchange for an equal number of subscription receipts issued in a private placement.
• The private placement successfully raised approximately US$100 million in gross proceeds, comprising US$22 million in cash and US$78 million in INJ tokens.
• The capital raised is intended to fund the company's Injective digital asset treasury strategy.
• Proposal 2 requests approval for a special resolution to amend the company's Articles of Continuance, removing existing restrictions on the transfer of common shares.
• The Board of Directors unanimously recommends that shareholders vote FOR both the Share Issuance Proposal and the Restriction Removal Proposal.
• As of the Record Date, September 15, 2025, there were 1,345,941 Common Shares issued and outstanding.
• Approval of the Share Issuance Proposal requires an ordinary resolution (simple majority), while the Restriction Removal Proposal requires a special resolution (two-thirds majority).
• Failure to approve these proposals would prevent the consummation of the private placement, requiring the return of all proceeds to purchasers, with the company solely responsible for approximately US$2.18 million in expenses.
• Upon issuance of the SR Common Shares, existing shareholders will experience significant dilution of their ownership interests.
• The Injective Foundation is expected to beneficially own 9,615,385 shares, or approximately 37% of the company's common shares, upon the issuance of the SR Common Shares.

Sentiment

Score: 7

Explanation: The filing outlines a significant capital raise and a strategic pivot towards digital assets, which could be positive for future growth. However, the extreme dilution for existing shareholders and the contingent nature of the transaction introduce considerable risk and potential negative market impact. The unanimous board recommendation provides some confidence in the internal alignment.

Positives

• Successfully secured approximately US$100 million in gross proceeds through a private placement, significantly bolstering the company's capital base.
• The acquisition of US$78 million in INJ tokens aligns with a strategic pivot towards a digital asset treasury strategy, potentially positioning the company for growth in the blockchain sector.
• The Board of Directors' unanimous recommendation for both proposals indicates strong internal alignment and confidence in the strategic direction.
• New employment agreements for CEO Shubha Dasgupta and Kendall Marin provide continuity and stability in key leadership roles.
• The planned appointment of an additional director with crypto industry expertise, in consultation with the Injective Foundation, could enhance strategic guidance and oversight in the digital asset space.

Negatives

• Existing shareholders will face extreme dilution, as the issuance of 24,642,700 SR Common Shares is approximately 18 times the current 1,345,941 outstanding shares.
• The potential sale of a large volume of SR Common Shares into the public market could materially and adversely affect the market price of the company's Common Shares.
• If the proposals are not approved, the company will be solely responsible for approximately US$2.18 million in private placement expenses, without receiving the capital.
• Both proposals are likely considered non-routine matters by the NYSE, meaning brokers cannot vote uninstructed shares, which could impact shareholder participation and approval rates.

Risks

• Failure to obtain shareholder approval for the Share Issuance Proposal and Restriction Removal Proposal will prevent the consummation of the private placement, necessitating alternative financing and incurring substantial additional costs.
• Existing shareholders will experience significant dilution of their ownership interests upon the issuance of the SR Common Shares.
• The sale of SR Common Shares into the public market could materially and adversely affect the market price of the company's Common Shares.
• Shareholders wishing to exercise dissent rights for the Restriction Removal Proposal must strictly comply with the technical and complex procedures of Section 190 of the Canada Business Corporations Act (CBCA), with failure potentially resulting in loss of these rights.
• The company may be unable to lawfully pay dissenting shareholders the fair value of their shares if it is or would be unable to pay its liabilities as they become due, or if the realizable value of its assets would be less than its aggregate liabilities.

Future Outlook

The company plans to adopt a policy where its treasury reserve assets will primarily consist of cash, cash equivalents, short-term investments, and INJ tokens, subject to market conditions. Following shareholder approval, the company will file a registration statement on Form S-1 within five business days to permit the resale of the SR Common Shares. An additional individual will be appointed to the Board of Directors prior to the Escrow Release Date, with consultation from the Injective Foundation regarding crypto industry expertise. Preliminary voting results will be announced at the Special Meeting, with final results published in a Current Report on Form 8-K within four business days.

Management Comments

• "The Board of Directors of the Company (the Board) has fixed the close of business on September 15, 2025 (the Record Date), as the record date for determining those Shareholders who are entitled to notice of and to vote at the Special Meeting."
• "The Board of Directors recommends that you vote your Common Shares: (1) FOR the Share Issuance Proposal; and (2) FOR the Restriction Removal Proposal."
• "The principal purpose of the Private Placement was to raise capital and acquire INJ tokens in connection with the Companys Injective digital asset treasury strategy."
• "The Board unanimously recommends a vote FOR approval of the Share Issuance Proposal."
• "The Board unanimously recommends a vote FOR approval of the Restriction Removal Proposal."

Industry Context

The company's strategy to acquire INJ tokens and establish them as a primary treasury reserve asset aligns with a growing trend among companies to integrate digital assets and blockchain technology into their financial strategies, particularly within the cryptocurrency and decentralized finance (DeFi) sectors. This move positions Pineapple Financial Inc. to potentially capitalize on the growth and adoption of the Injective blockchain ecosystem, reflecting a broader industry shift towards digital asset integration and treasury management.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• Members of the Board (Messrs. Dasgupta, Marin, Green, Baron, and Giannoukakis) have entered into voting agreements with the company and one of the purchasers to support the Shareholder Approval proposals.
• Shubha Dasgupta (CEO) and Kendall Marin will enter into new employment agreements with terms consistent with their prior compensation and benefits, as required by the Securities Purchase Agreement.
• Purchasers in the Private Placement, including those associated with the Injective Foundation (the Investor), may have interests that differ from those of existing shareholders. The Injective Foundation will beneficially own approximately 37% of the company's common shares upon issuance.

Stakeholder Impact

• Shareholders: Will experience extreme dilution of their ownership interests (over 18x) upon the issuance of 24,642,700 SR Common Shares. The market price of existing shares could be adversely affected. Registered shareholders have dissent rights for the Restriction Removal Proposal.
• Purchasers (Private Placement Investors): Will receive a significant stake in the company (24,642,700 SR Common Shares), with the Injective Foundation becoming a major beneficial owner (approx. 37%), contingent on shareholder approval.
• Management/Board: Board members have committed to supporting the proposals through voting agreements. The CEO and another officer will receive new employment agreements, providing stability.
• Company: Stands to gain US$100 million in capital (cash and INJ tokens) to execute its digital asset treasury strategy if proposals are approved. Faces a financial liability of US$2.18 million in expenses if the proposals fail.

Next Steps

• Shareholders will vote on the Share Issuance Proposal and Restriction Removal Proposal at the Special Meeting on October 31, 2025.
• If approved, the company will issue 24,642,700 SR Common Shares to the holders of Subscription Receipts.
• If approved, the company will amend its Articles of Continuance to remove the restriction on common share transfers.
• Within five business days of receiving Shareholder Approval, the company will file a registration statement on Form S-1 to permit the resale of the SR Common Shares.
• One additional individual will be appointed to the Board of Directors prior to the Escrow Release Date.
• The company will adopt a formal policy for its treasury reserve assets, designating INJ tokens as a primary asset.
• Preliminary voting results will be announced at the Special Meeting, with final results published in a Current Report on Form 8-K.

Key Dates

Keywords

Pineapple Financial, SEC filing, DEF 14A, proxy statement, special meeting, share issuance, private placement, subscription receipts, INJ tokens, Injective blockchain, digital asset treasury, shareholder approval, transfer restrictions, corporate governance, dilution, NYSE American, capital raise, cryptocurrency